Natco Pharma has announced its intention to acquire a 35.75 percent equity stake in South Africa’s Adcock Ingram Holdings, in a deal valued at approximately INR 2,000 crore. This transaction is expected to make Natco the second-largest shareholder, while Bidvest will retain a 64.25 percent holding.

Under the terms of the offer, Natco will purchase around 51.64 million shares at a cash price of ZAR 75 per share. The acquisition will be carried out through a scheme of arrangement aimed at buying out minority shareholders, following which Adcock Ingram may be delisted from the Johannesburg Stock Exchange and operate as a privately held company.

Natco considers this move a strategic entry into the Southern African pharmaceutical market, offering access to new growth opportunities and revenue streams in one of the region’s most established healthcare sectors. Adcock Ingram is a leading manufacturer and supplier of hospital, critical care, generic, and over-the-counter products in South Africa, with reported revenue of ZAR 9.6 billion in the last fiscal year.

The transaction is expected to close within four months, subject to regulatory approvals and shareholder consent. This acquisition aligns with Natco’s global expansion strategy and reflects confidence in Adcock Ingram’s strong market position and South Africa’s growing pharmaceutical landscape.